Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

Science. 2000 Oct 27;290(5492):767-73. doi: 10.1126/science.290.5492.767.

Abstract

Lentiviral delivery of glial cell line-derived neurotrophic factor (lenti-GDNF) was tested for its trophic effects upon degenerating nigrostriatal neurons in nonhuman primate models of Parkinson's disease (PD). We injected lenti-GDNF into the striatum and substantia nigra of nonlesioned aged rhesus monkeys or young adult rhesus monkeys treated 1 week prior with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Extensive GDNF expression with anterograde and retrograde transport was seen in all animals. In aged monkeys, lenti-GDNF augmented dopaminergic function. In MPTP-treated monkeys, lenti-GDNF reversed functional deficits and completely prevented nigrostriatal degeneration. Additionally, lenti-GDNF injections to intact rhesus monkeys revealed long-term gene expression (8 months). In MPTP-treated monkeys, lenti-GDNF treatment reversed motor deficits in a hand-reach task. These data indicate that GDNF delivery using a lentiviral vector system can prevent nigrostriatal degeneration and induce regeneration in primate models of PD and might be a viable therapeutic strategy for PD patients.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Aging
  • Animals
  • Antigens, CD / analysis
  • Dihydroxyphenylalanine / analogs & derivatives*
  • Dihydroxyphenylalanine / metabolism
  • Disease Models, Animal
  • Dopamine / metabolism*
  • Female
  • Gene Expression
  • Genetic Therapy*
  • Genetic Vectors
  • Glial Cell Line-Derived Neurotrophic Factor
  • Lentivirus / genetics
  • Macaca mulatta
  • Neostriatum / metabolism
  • Neostriatum / pathology
  • Nerve Degeneration / prevention & control*
  • Nerve Growth Factors*
  • Nerve Tissue Proteins / genetics*
  • Nerve Tissue Proteins / metabolism
  • Nerve Tissue Proteins / therapeutic use
  • Neurons / enzymology
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology
  • Parkinson Disease / physiopathology
  • Parkinson Disease / therapy*
  • Parkinsonian Disorders / metabolism
  • Parkinsonian Disorders / pathology
  • Parkinsonian Disorders / physiopathology
  • Parkinsonian Disorders / therapy
  • Psychomotor Performance
  • Substantia Nigra / metabolism
  • Substantia Nigra / pathology
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • Antigens, CD
  • Glial Cell Line-Derived Neurotrophic Factor
  • Nerve Growth Factors
  • Nerve Tissue Proteins
  • fluorodopa F 18
  • Dihydroxyphenylalanine
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Tyrosine 3-Monooxygenase
  • Dopamine